VCRB yields 4.55% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 9
Combined, VCRB + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VCRB + JNJ for your $10,000?
This actively managed fund seeks to provide broadly diversified exposure predominantly to the U.S. investment-grade bond market. The low-cost fund invests in U.S. Treasury, mortgage-backed, and corporate securities of varying yields and maturities (short-, intermediate-, and long-term issues). Using a disciplined, risk-controlled approach, the fund seeks to outperform the broad investment-grade market through security selection, sector allocation, and, to a lesser extent, duration decisions. Like other bond funds, the fund is subject to interest rate risk; increases in interest rates may cause the price of the bonds in the portfolio to decrease, reducing the fund’s NAV. Since the fund invests in all major segments and maturities of the investment-grade fixed income market, investors may consider the fund as a core bond holding.The Core Bond ETF is a stand alone product and is separate and distinct from the Vanguard Core Bond Fund (VCOBX and VCORX). Differences in scale, certain investment processes, and underlying holdings are expected to produce different investment returns by the funds.
Full VCRB Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.